

POSTER PRESENTATION

Open Access

Initial characterization of drug resistant cancer stem cells isolated from primary brain tumors (astrocytoma) cell lines generated from Saudi patients

Ishaq Khan^{1*}, Mohammed Bangash³, Saleh S Baeesa³, Awatif Jamal³, Hanadi Qashqari², Adel Abuzenadah¹, Mohammed H. AlQahtani¹, Ghazi Damanhour², Hans-Juergen Schulten¹, Deema Hussein², Adeel Chaudhary¹

From 2nd International Genomic Medical Conference (IGMC 2013)
Jeddah, Kingdom of Saudi Arabia. 24-27 November 2013

Background

The Cancer Stem Cells (CSCs) hypothesis proposes that malignant brain tumours are organized into aberrant cell hierarchies where a subset of parent CSCs replicate asymmetrically and unlimitedly to produce differentiated daughter cell [1,2]. These parent CSCs are highly adaptive and resistant to the chemotherapeutic drugs [3]. Developing new drugs that target CSCs requires a comprehensive understanding of the pharmacogenomics behavior of these cells [4,5]. Such understanding requires reliable *in vitro* and *in vivo* models that represent the beneficial patients. This project is set out to: i) Establish a collection of astrocytoma cell lines generated from Saudi patients, ii) Select drug resistant brain tumour CSCs, iii) Characterize drug resistant brain tumour CSCs individually, and iv) Deduce common features for drug resistant brain tumour CSCs.

Materials and methods

A range of methodologies will be applied including, tumour cell line derivation methods, the clonogenic selection assay, cytogenetics profiles, neuronal cancer stem cells characterisation assays and *in vivo* tumourigenic assays.

Results

Optimisation of methods used to establish astrocytoma cell lines generated from Saudi patients was completed.

* Correspondence: ishaq_gene101@yahoo.com

¹Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, KSA

Full list of author information is available at the end of the article

To date two novel primary astrocytoma cell lines have been derived. Full clinical data related to the cell lines was retrieved. Currently, optimisation of the clonogenic selection assay and immunostaining for cancer stem cells markers are under progress.

Conclusions

Successful retrieval of primary astrocytoma cell lines was possible to accomplish. Important clinical information data relevant to the cell lines were obtained providing clear identification reference. Further work is required for the characterization of the drug resistant cancer stem cell component within these cell lines. Once completed, this research will assist in understanding some of the molecular mechanisms relevant to drug resistance, especially for patients in the Kingdom of Saudi Arabia.

Authors' details

¹Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, KSA. ²King Fahd Medical Research Centre, King Abdulaziz University, Jeddah, KSA. ³Medical College, King Abdulaziz University, Jeddah, KSA.

Published: 2 April 2014

References

1. Dirks PB: Brain tumour stem cells: the undercurrents of human brain cancer and their relationship to neural stem cells. *Philosophical Transactions of the Royal Society B: Biological Sciences* 2008, **363**(1489):139-152.
2. Khoshnevisan A: An overview of therapeutic approaches to brain tumor stem cells. *Medical journal of the Islamic Republic of Iran* 2012, **26**(1):31.
3. Quezada C, Garrido W, Oyarzún C, Fernández K, et al: 5' ectonucleotidase mediates multiple drug resistance in glioblastoma multiforme cells. *Journal of cellular physiology* 2013, **228**(3):602-608.

4. Maugeri-Saccà M, Vigneri P, De Maria R: **Cancer stem cells and chemosensitivity.** *Clinical Cancer Research* 2011, **17**(15):4942-4947.
5. Reya T, Morrison SJ, Clarke MF, Weissman IL: **Stem cells, cancer, and cancer stem cells.** *Nature* 2001, **414**(6859):105-111.

doi:10.1186/1471-2164-15-S2-P53

Cite this article as: Khan *et al.*: Initial characterization of drug resistant cancer stem cells isolated from primary brain tumors (astrocytoma) cell lines generated from Saudi patients. *BMC Genomics* 2014 **15**(Suppl 2):P53.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

